Nov 14, 2017 - Worry whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.
Nov 14, 2017 - Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Nov 13, 2017 - Encouraging results for one of its drugs in solid tumor cancers are sparking interest in the clinical-stage company.
Nov 11, 2017 - Nektar, Sage, and Valeant stocks ranked among the biggest winners this week. But will their winning ways continue?
Nov 10, 2017 - Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Nov 09, 2017 - The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.
Nov 08, 2017 - Third-quarter financial results that impressed kindled investor enthusiasm.
Nov 08, 2017 - Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Nov 07, 2017 - It was another lackluster quarter from the diabetes specialist.
Oct 30, 2017 - Not all diabetes stocks are created equally.